# Carole Vuillerot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9572486/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 43 papers | 1,823 citations | 516710 16 h-index | 276875 41 g-index |
| 49 all docs | 49 docs citations | 49 times ranked | 1792 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders, 2018, 28, 103-115. | 0.6 | 584 |
| 2 | Emerging health challenges for children with physical disabilities and their parents during the COVID-19 pandemic: The ECHO French survey. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101429. | 2.3 | 120 |
| 3 | Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Developmental Medicine and Child Neurology, 2010, 52, 60-65. | 2.1 | 114 |
| 4 | Motor and respiratory heterogeneity in Duchenne patients: Implication for clinical trials. European Journal of Paediatric Neurology, 2012, 16, 149-160. | 1.6 | 112 |
| 5 | Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. PLoS ONE, 2018, 13, e0201004. | 2.5 | 107 |
| 6 | Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, The, 2017, 16, 513-522. | 10.2 | 95 |
| 7 | Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124. | 5.3 | 93 |
| 8 | Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2022, 21, 42-52. | 10.2 | 89 |
| 9 | Responsiveness of the Motor Function Measure in Patients With Spinal Muscular Atrophy. Archives of Physical Medicine and Rehabilitation, 2013, 94, 1555-1561. | 0.9 | 73 |
| 10 | Motor Function Measure: Validation of a Short Form for Young Children With Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2013, 94, 2218-2226. | 0.9 | 63 |
| 11 | Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet Journal of Rare Diseases, 2020, 15, 148. | 2.7 | 63 |
| 12 | Responsiveness of the Motor Function Measure in Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2012, 93, 2251-2256.e1. | 0.9 | 46 |
| 13 | Self-Perception of Quality of Life by Adolescents with Neuromuscular Diseases. Journal of Adolescent Health, 2010, 46, 70-76. | 2.5 | 27 |
| 14 | Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies. Neurology, 2019, 93, e1932-e1943. | 1.1 | 23 |
| 15 | Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. Developmental Medicine and Child Neurology, 2018, 60, 185-191. | 2.1 | 19 |
| 16 | Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy. Neurology and Therapy, 2020, 9, 575-584. | 3.2 | 18 |
| 17 | Rasch Analysis of the Motor Function Measure in Patients With Congenital Muscle Dystrophy and Congenital Myopathy. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2086-2095. | 0.9 | 16 |
| 18 | Perceived impact of lockdown on daily life in children with physical disabilities and their families during the COVIDâ€19 pandemic. Child: Care, Health and Development, 2022, 48, 942-955. | 1.7 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscular Disorders, 2020, 30, 959-969. | 0.6 | 15 |
| 20 | Influence of a two-year steroid treatment on body composition as measured by dual X-ray absorptiometry in boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2014, 24, 467-473. | 0.6 | 12 |
| 21 | English Cross-Cultural Translation and Validation of the Neuromuscular Score: A System for Motor Function Classification in Patients With Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2014, 95, 2064-2070.e1. | 0.9 | 11 |
| 22 | Quality of life and functional outcome in early school-aged children after neonatal stroke: A prospective cohort study. European Journal of Paediatric Neurology, 2014, 18, 347-353. | 1.6 | 9 |
| 23 | Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy. PLoS ONE, 2020, 15, e0238786. | 2.5 | 9 |
| 24 | Is Going Beyond Rasch Analysis Necessary to Assess the Construct Validity of a Motor Function Scale?. Archives of Physical Medicine and Rehabilitation, 2018, 99, 1776-1782.e9. | 0.9 | 8 |
| 25 | The motor function measure to study limitation of activity in children and adults with Charcot-Marie-Tooth disease. Annals of Physical and Rehabilitation Medicine, 2014, 57, 587-599. | 2.3 | 7 |
| 26 | Elementary visuospatial perception deficit in children with neurodevelopmental disorders. Developmental Medicine and Child Neurology, 2021, 63, 457-464. | 2.1 | 7 |
| 27 | Development and validation of a motor function classification in patients with neuromuscular disease: The NM-Score. Annals of Physical and Rehabilitation Medicine, 2013, 56, 673-686. | 2.3 | 6 |
| 28 | Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregiversâ€™ perspective: a two-part study. BMC Neurology, 2021, 21, 143. | 1.8 | 6 |
| 29 | Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy. European Journal of Paediatric Neurology, 2022, 36, 78-83. | 1.6 | 6 |
| 30 | A Patient-Centered Evaluation of Meaningful Change on the 32-Item Motor Function Measure in Spinal Muscular Atrophy Using Qualitative and Quantitative Data. Frontiers in Neurology, 2021, 12, 770423. | 2.4 | 6 |
| 31 | Motor function performance in individuals with RYR1 â€related myopathies. Muscle and Nerve, 2019, 60, 80-87. | 2.2 | 5 |
| 32 | Responsiveness and Minimal Clinically Important Difference of the Motor Function Measure in Collagen VI-Related Dystrophies and Laminin Alpha2-Related Muscular Dystrophy. Archives of Physical Medicine and Rehabilitation, 2021, 102, 604-610. | 0.9 | 5 |
| 33 | State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Archives De Pediatrie, 2020, 27, 7S40-7S44. | 1.0 | 5 |
| 34 | Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Pediatric Pulmonology, 2022, 57, 1505-1512. | 2.0 | 5 |
| 35 | Validation of a simple screening test for elementary visuo-spatial perception deficit. Annals of Physical and Rehabilitation Medicine, 2020, 63, 302-308. | 2.3 | 4 |
| 36 | Cross-cultural Adaptation and Multi-centric Validation of the Motor Function Measure Chinese Version (MFM-32-CN) for Patients with Neuromuscular Diseases. Developmental Neurorehabilitation, 2020, 23, 210-217. | 1.1 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | From singular to holistic: Approaches in pediatric rehabilitation medicine for children with cerebral palsy. Annals of Physical and Rehabilitation Medicine, 2020, 63, 391-392. | 2.3 | 3 |
| 38 | Construction and feasibility study of the SOFMER Activity Score (SAS), a new assessment of physical and cognitive activity. Annals of Physical and Rehabilitation Medicine, 2018, 61, 315-322. | 2.3 | 2 |
| 39 | E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 1st eNMD Congress: Nice, France, March 22-23, 2019. Journal of Neuromuscular Diseases, 2021, 8, 743-754. | 2.6 | 2 |
| 40 | Mathematical Disease Progression Modeling in Type 2/3 Spinal Muscular Atrophy. Muscle and Nerve, 2018, 58, 528-535. | 2.2 | 1 |
| 41 | Hand Dexterity: Design for Automatic Evaluation of Item 18 of MFM Scale. Procedia CIRP, 2019, 84, 514-519. | 1.9 | 1 |
| 42 | User-Centered Development of an Information System in Patientâ€™s Motor Capacity Evaluation. Springer Proceedings in Mathematics and Statistics, 2017, , 121-131. | 0.2 | 1 |
| 43 | Determining the Interrater Reliability of the SOFMER Activity Score (version 2) for Individuals in Rehabilitation Centers. Archives of Physical Medicine and Rehabilitation, 2021, , . | 0.9 | 0 |